mirtazapine and Depression, Involutional studies

Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.

Research Excerpts

Excerpt	Relevance	Reference
"The purpose of the present paper was to evaluate the effectiveness of mirtazapine orally disintegrating tablets for nausea and sleep disturbance, which are common and distressing symptoms of cancer."	9.13	Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. ( Kim, JM; Kim, KM; Kim, KS; Kim, SW; Kim, YC; Shin, IS; Yang, SJ; Yoon, JS, 2008)
"The objective of this study was to assess the clinical response and safety of mirtazapine in the pediatric population with a diagnosis of functional nausea and nausea associated with functional dyspepsia postprandial distress syndrome."	8.12	Effect of Mirtazapine on Nausea in Children with Functional Nausea and Functional Dyspepsia Postprandial Distress Syndrome. ( Hyman, PE; Iglesias-Escabi, IM; Kleesattel, D; LeBlanc, C; McDaniel, LS; Reuther, E; Santucci, NR, 2022)
"We report the case of an African American patient who developed drug-associated acute pancreatitis without hypertriglyceridemia, after being treated with mirtazapine for major depressive disorder (MDD)."	8.12	Mirtazapine-associated acute pancreatitis in a patient with insomnia and co-occurring psychiatric disorders. ( Aguiar, T; Chakravorty, S; He, S; Ikner, TP; Taylor, BV; Thakur, NP, 2022)
" Here, we report the case of a 20-year-old man with severe social anxiety disorder, major depressive disorder, insomnia and attenuated psychotic symptoms despite ongoing treatment with cognitive behavioural therapy and mirtazapine who was treated with adjunctive cannabidiol (CBD) in doses between 200 and 800 mg/day for 6 months."	7.96	Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. ( Amminger, GP; Berger, M; Li, E, 2020)
"This study evaluated the clinical efficacy of mirtazapine and its effect on serum brain-derived neurotrophic factor (BDNF) and tumor necrosis factor-α (TNF-α) levels in patients of major-depressive disorder (MDD) with severe depression."	7.83	Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression. ( Bhatia, MS; Gupta, K; Gupta, LK; Gupta, R; Tripathi, AK, 2016)
" The provisional diagnosis of irritable bowel syndrome was performed and pinaverium bromide was started."	7.80	Acute hepatitis after starting pinaverium bromide in a patient taking mirtazapine. ( Tak, S, 2014)
"To report the use of Mirtazapine in the treatment of anorexia nervosa with depression primarily regarding its propensity for weight gain."	7.74	Mirtazapine for anorexia nervosa with depression. ( Baharudin, A; Daud, TI; Jaafar, NR; Rahman, FN, 2007)
"Several studies have shown that olanzapine is effective in weight restoration and maintenance for patients with anorexia nervosa (AN)."	7.73	Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression. ( Chou, YH; Shiah, IS; Wang, TS, 2006)
"To examine the effects of the noradrenergic and specific serotonergic antidepressant mirtazapine on motor cortex excitability in epilepsy patients with depression and in healthy controls, using transcranial magnetic stimulation (TMS)."	7.73	Mirtazapine increases cortical excitability in healthy controls and epilepsy patients with major depression. ( Gerschlager, W; Langosch, JM; Münchau, A; Orth, M; Rothwell, JC; Trimble, MR, 2005)
"Mirtazapine is an antidepressant with a mechanism that involves activating serotonin (5-HT1) receptors."	6.47	Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. ( Huang, KC; Lee, WK; Li, TC; Shiah, IS; Sun, CJ; Tzang, RF, 2011)
"Mirtazapine has demonstrated superior tolerability to the tricyclic antidepressants and trazodone, primarily on account of its relative absence of anticholinergic, adrenergic and serotonin-related adverse effects, in particular gastrointestinal adverse effects and sexual dysfunction."	6.40	A risk-benefit assessment of mirtazapine in the treatment of depression. ( Kasper, S; Praschak-Rieder, N; Tauscher, J; Wolf, R, 1997)
"Mirtazapine has demonstrated superior tolerability to the tricyclic antidepressants, primarily on account of its relative absence of anticholinergic, adrenergic and serotonin-related adverse effects."	5.31	Occurrence of mirtazapine-induced delirium in organic brain disorder. ( Bailer, U; Fischer, P; Kasper, S; Küfferle, B; Stastny, J, 2000)
"This report used acute treatment data from a clinically representative sample of outpatients with nonpsychotic major depressive disorder (N = 665) participating in the Combining Medications to Enhance Depression Outcomes trial, who received up to 12 weeks of escitalopram, escitalopram plus bupropion SR, or venlafaxine XR plus mirtazapine."	5.30	The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. ( Carmody, TJ; De La Garza, N; Grannemann, BD; Killian, MO; Rush, AJ; Trivedi, MH, 2019)
"The purpose of the present paper was to evaluate the effectiveness of mirtazapine orally disintegrating tablets for nausea and sleep disturbance, which are common and distressing symptoms of cancer."	5.13	Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. ( Kim, JM; Kim, KM; Kim, KS; Kim, SW; Kim, YC; Shin, IS; Yang, SJ; Yoon, JS, 2008)
"This study aimed to compare the effectiveness of mirtazapine and imipramine on not only the distressing symptoms of cancer patients such as pain, nausea, vomiting, appetite loss, and sleep disturbances but also depressive and anxiety symptoms."	5.13	Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. ( Akbiyik, DI; Alkis, N; Cankurtaran, ES; Ozalp, E; Soygur, H; Turhan, L, 2008)
"We obtained access to IPD from seven placebo-controlled trials comparing bupropion, duloxetine, escitalopram, mirtazapine, paroxetine or venlafaxine with placebo in the acute phase treatment of major depression (total n = 2803)."	5.01	Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. ( Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S, 2019)
"The objective of this study was to assess the clinical response and safety of mirtazapine in the pediatric population with a diagnosis of functional nausea and nausea associated with functional dyspepsia postprandial distress syndrome."	4.12	Effect of Mirtazapine on Nausea in Children with Functional Nausea and Functional Dyspepsia Postprandial Distress Syndrome. ( Hyman, PE; Iglesias-Escabi, IM; Kleesattel, D; LeBlanc, C; McDaniel, LS; Reuther, E; Santucci, NR, 2022)
"We report the case of an African American patient who developed drug-associated acute pancreatitis without hypertriglyceridemia, after being treated with mirtazapine for major depressive disorder (MDD)."	4.12	Mirtazapine-associated acute pancreatitis in a patient with insomnia and co-occurring psychiatric disorders. ( Aguiar, T; Chakravorty, S; He, S; Ikner, TP; Taylor, BV; Thakur, NP, 2022)
" Here, we report the case of a 20-year-old man with severe social anxiety disorder, major depressive disorder, insomnia and attenuated psychotic symptoms despite ongoing treatment with cognitive behavioural therapy and mirtazapine who was treated with adjunctive cannabidiol (CBD) in doses between 200 and 800 mg/day for 6 months."	3.96	Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. ( Amminger, GP; Berger, M; Li, E, 2020)
"This study evaluated the clinical efficacy of mirtazapine and its effect on serum brain-derived neurotrophic factor (BDNF) and tumor necrosis factor-α (TNF-α) levels in patients of major-depressive disorder (MDD) with severe depression."	3.83	Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression. ( Bhatia, MS; Gupta, K; Gupta, LK; Gupta, R; Tripathi, AK, 2016)
" The provisional diagnosis of irritable bowel syndrome was performed and pinaverium bromide was started."	3.80	Acute hepatitis after starting pinaverium bromide in a patient taking mirtazapine. ( Tak, S, 2014)
" Authors report a case of a 65-year old male patient who was treated with venlafaxine-mirtazapine combination for recurrent depression."	3.79	[Antidepressant treatment associated hyponatremia -- case report]. ( Bognár, Z; Gazdag, G; Vonyik, G, 2013)
"A 40-year old woman with a history of acute psychotic symptoms developed agranulocytosis and neutropenia after starting therapy that included lamotrigine, mirtazapine, quetiapine, and venlafaxine."	3.78	Fatal agranulocytosis associated with psychotropic medication use. ( Al-Najjar, T; Ali, BA; Nazer, LH; Shankar, G, 2012)
" We report a case with no previous history of bipolar disorder, whereas developed full-blown psychotic manic symptoms soon after switch from fluoxetine to mirtazapine."	3.75	Antidepressant-associated mania: soon after switch from fluoxetine to mirtazapine in an elderly woman with mixed depressive features. ( Liang, KY; Liao, SC; Liu, CC, 2009)
"To report the use of Mirtazapine in the treatment of anorexia nervosa with depression primarily regarding its propensity for weight gain."	3.74	Mirtazapine for anorexia nervosa with depression. ( Baharudin, A; Daud, TI; Jaafar, NR; Rahman, FN, 2007)
"Several studies have shown that olanzapine is effective in weight restoration and maintenance for patients with anorexia nervosa (AN)."	3.73	Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression. ( Chou, YH; Shiah, IS; Wang, TS, 2006)
"To examine the effects of the noradrenergic and specific serotonergic antidepressant mirtazapine on motor cortex excitability in epilepsy patients with depression and in healthy controls, using transcranial magnetic stimulation (TMS)."	3.73	Mirtazapine increases cortical excitability in healthy controls and epilepsy patients with major depression. ( Gerschlager, W; Langosch, JM; Münchau, A; Orth, M; Rothwell, JC; Trimble, MR, 2005)
" This might lead to polypharmacy and increase adverse events representing major threats to the quality of health care, especially in palliative care situations."	3.11	What is the effectiveness and safety of mirtazapine versus escitalopram in alleviating cancer-associated poly-symptomatology (the MIR-P study)? A mixed-method randomized controlled trial protocol. ( Alexandre, M; Economos, G; Glehen, O; Haesebaert, J; Perceau-Chambard, E; Subtil, F; Villeneuve, L, 2022)
"One hundred one patients with major depressive disorder were randomized at baseline to receive either mirtazapine or SSRI treatment."	3.11	Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8 weeks. ( Bandou, H; Kato, M; Kinoshita, T; Koshikawa, Y; Naito, M; Nishida, K; Sakai, S; Takekita, Y, 2022)
"Escitalopram was significantly more effective in daily activity, feeling slowed down and concentration difficulty, while mirtazapine was significantly more effective in improving sleep, appetite and weight of MDD."	3.11	Difference in the regulation of biological rhythm symptoms of Major depressive disorder between escitalopram and mirtazapine. ( Cao, L; Chen, Y; Fang, Y; Hong, W; Huang, H; Huang, Q; Kong, S; Lyu, D; Peng, D; Qian, N; Wang, F; Wei, Z; Wu, C; Wu, Z; Yang, W; Zhang, M; Zhao, J, 2022)
"When mirtazapine was added on for SSRIs non-responders at week 4, the remission rate increased by 5% and HAM-D score improved by 4 points."	2.84	Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. ( Bandou, H; Hatashita, Y; Kato, M; Kinoshita, T; Koshikawa, Y; Nishida, K; Onohara, A; Sakai, S; Serretti, A; Sunada, N; Takekita, Y, 2017)
"Bupropion (BUP) is a norepinephrine-dopamine reuptake inhibitor frequently used in prisons."	2.82	Bupropion XL unapproved use in the prisons: Two cases focused on the bupropion pharmacology. ( Oravecz, R; Stuhec, M, 2022)
"Most patients with major depressive disorder (MDD) report clinically significant sleep problems."	2.80	Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. ( Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR, 2015)
" Step I randomization compares the minimum and the maximum dosing strategy for the first-line antidepressant."	2.80	Strategic use of new generation antidepressants for depression: SUN(^_^) D protocol update and statistical analysis plan. ( Akechi, T; Furukawa, TA; Guyatt, GH; Hayasaka, Y; Inagaki, M; Kato, T; Mantani, A; Miki, K; Ogawa, Y; Shimodera, S; Shinohara, K; Tajika, A; Takeshima, N; Tanaka, S; Watanabe, N; Yamada, M; Yonemoto, N, 2015)
"It involved 88 terminally ill cancer patients from University of Malaya Medical Centre, Kuala Lumpur, Malaysia."	2.79	Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study. ( Boks, MP; de Wit, NJ; Ng, CG; Roes, KC; Sulaiman, AH; Tan, SB; Zainal, NZ, 2014)
"Prior studies have suggested that major depressive disorder (MDD) with pre-adult onset represents a distinct subtype with greater symptom severity and higher rates of suicidal ideation."	2.78	Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. ( Balasubramani, GK; Kurian, B; Rush, AJ; Sung, SC; Trivedi, MH; Warden, D; Wisniewski, SR; Zisook, S, 2013)
"Patients aged 60 years or more with major depressive disorder were recruited at the outpatient service of a specialized mental health centre."	2.78	Effects of mirtazapine on the sleep wake rhythm of geriatric patients with major depression: an exploratory study with actigraphy. ( Fresan, A; Jiménez-Genchi, A; Muñoz-Delgado, J; Roche, A; Rothschild-Fuentes, B; Sánchez-Ferrer, JC, 2013)
"Mirtazapine treatment resulted in a significant improvement in mean Hamilton Depression Rating Scale total score at the end of the study (P < 0."	2.77	Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. ( Baumann, P; Brocard, M; Crettol, S; Eap, CB; Golay, KP; Harenberg, S; Hilleret, H; Jaquenoud Sirot, E; Jonzier-Perey, M; Kemmerling, K; Lima, CA; Perrenoud, P; Vandel, P; Zullino, DF, 2012)
"The co-occurrence of substance use disorder (SUD) and major depressive disorder (MDD) is common and is often thought to impair response to antidepressant therapy."	2.77	Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. ( Balasubramani, GK; Davis, LL; Fava, M; Gaynes, BN; Howland, RH; Pilkinton, P; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2012)
" Second we do not know which dosage we should be aiming at with that antidepressant."	2.76	Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. ( Akechi, T; Furukawa, TA; Inagaki, M; Miki, K; Shimodera, S; Watanabe, N; Yamada, M; Yonemoto, N, 2011)
"A total of 60 MDD patients with a score above 18 on the Hamilton Anxiety Rating Scale (HARS) were randomly assigned to 8 weeks of fixed dosing treatment with mirtazapine (15-30 mg/day) and paroxetine (10-20 mg/day)."	2.76	Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. ( Cho, HB; Jeong, HS; Jung, JY; Kim, J; Kim, JE; Kim, TS; Lyoo, IK; Shin, E; Yoon, SJ, 2011)
"Baseline suicidal ideation was associated with greater depressive severity, childhood neglect, childhood abuse, early major depressive disorder onset, greater psychiatric comorbidity, and worse functioning and quality of life."	2.76	Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. ( Fava, M; Kallenberg, G; Lebowitz, B; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2011)
"Twenty-four untreated patients with major depressive disorder (according to Structured Clinical Interview for DSM-IV) were enrolled in a prospective, randomized, 4-week trial with mirtazapine and venlafaxine."	2.76	Different effects of mirtazapine and venlafaxine on brain activation: an open randomized controlled fMRI study. ( Bokde, AL; Brückmann, H; Frodl, T; Hampel, H; Koutsouleris, N; Linn, J; Meisenzahl, E; Möller, HJ; Scheuerecker, J; Schoepf, V; Wiesmann, M, 2011)
" Non-responders on combination therapy had the dosage of both drugs increased by 50%."	2.74	Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. ( Blier, P; Boucher, N; de Montigny, C; Debonnel, G; Gobbi, G; Hébert, C; Turcotte, JE, 2009)
"Mirtazapine augmentation is a good choice for the treatment of SSRI-induced sexual dysfunction, and the results are typically seen later after 4-8 weeks."	2.73	Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. ( Bozkurt, A; Cansever, A; Doruk, A; Karlidere, T; Ozgen, F; Ozmenler, NK; Ozsahin, A; Sutcigil, L; Uzun, O; Yetkin, S, 2008)
"In mirtazapine-treated females homozygous for the A-allele compared to AG/GG-carriers, HAMD-17 scores during the study period were constantly and markedly lower, but not statistically different."	2.73	A monoamine oxidase B gene variant and short-term antidepressant treatment response. ( Dahmen, N; Kohnen, R; Müller, MJ; Rujescu, D; Stassen, HH; Szegedi, A; Tadić, A, 2007)
"Mirtazapine has a dual-action profile, combining the enhancement of the noradrenergic neurotransmitter system with specific actions on particular serotonergic receptor subtypes."	2.73	Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. ( Choi, MJ; Kang, RH; Lee, MS; Paik, JW; Wong, ML, 2007)
"Mirtazapine is a third-generation antidepressant with a dual mode of action."	2.72	Intravenous mirtazapine is safe and effective in the treatment of depressed inpatients. ( Egger, C; Eichberger, G; Hinterhuber, H; Hofmann, P; Kasper, S; Konstantinidis, A; Mühlbacher, M; Nickel, M; Nimmerrichter, A; Schubert, H; Stuppaeck, C, 2006)
" Both treatments were administered in a rapidly escalating dosing regimen."	2.72	Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. ( Baker, RA; Benkert, O; Heinrich, C; Heukels, A; Kohnen, R; Philipp, M; Schutte, AJ; Simmons, JH; Szegedi, A; van der Vegte-Senden, M, 2006)
"Tranylcypromine was associated with significantly less symptom reduction and greater attrition due to intolerance."	2.72	Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. ( Biggs, MM; Davis, L; Fava, M; Luther, JF; McGrath, PJ; Niederehe, G; Nierenberg, AA; Rush, AJ; Shores-Wilson, K; Stewart, JW; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR, 2006)
"Major depressive disorders have a significant impact on children and adolescents, including on educational and vocational outcomes, interpersonal relationships, and physical and mental health and well-being."	2.72	New generation antidepressants for depression in children and adolescents: a network meta-analysis. ( Badcock, PB; Bailey, AP; Cox, GR; Hetrick, SE; McKenzie, JE; Meader, N; Merry, SN; Moller, CI; Sharma, V, 2021)
"Mirtazapine pharmacokinetic (PK) data from patients on long-term treatment for major depression have never been investigated."	2.71	Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study. ( Ahlner, J; Bengtsson, F; Prochazka, J; Reis, M; Sitsen, A, 2005)
"Imipramine has often been used as positive control in studies investigating the efficacy of new antidepressants."	2.71	Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed? ( Birkenhäger, TK; Bruijn, JA; Moleman, P; van den Broek, WW; Vulto, AG, 2005)
"Mirtazapine acts as an antagonist at presynaptic alpha(2)-receptors and at postsynaptic 5-hydroxytryptamine (5-HT)(2), 5-HT(3) and histamine H(1) receptors."	2.71	Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. ( Baghai, T; Ella, R; Eser, D; Möller, HJ; Padberg, F; Rupprecht, R; Schüle, C; Zwanzger, P, 2003)
"The Hamilton Depression Rating Scale-17 and Geriatric Depression Scale, severity of adverse events and dosing compliance indexes, and discontinuations due to adverse events."	2.71	Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. ( Hollander, SB; Kremer, C; Murphy, GM; Rodrigues, HE; Schatzberg, AF, 2004)
"Mirtazapine has been shown to acutely inhibit cortisol secretion in healthy subjects."	2.71	Mirtazapine acutely inhibits salivary cortisol concentrations in depressed patients. ( Baghai, T; Hennig, J; Laakmann, G; Schüle, C, 2004)
"Mirtazapine was begun at 15 mg at bedtime, with possible titration to 30 mg at bedtime per physician's discretion after week 1."	2.70	A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. ( Carpenter, LL; Price, LH; Yasmin, S, 2002)
" There was no evidence supporting efficacy of the flexible dosing over the fixed low dose of SSRIs (ROR 0."	2.66	No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review. ( Cipriani, A; Cowen, PJ; Furukawa, TA; Leucht, S; Salanti, G, 2020)
"We did a systematic review and dose-response meta-analysis of double-blind, randomised controlled trials that examined fixed doses of five selective serotonin reuptake inhibitors (SSRIs; citalopram, escitalopram, fluoxetine, paroxetine, and sertraline), venlafaxine, or mirtazapine in the acute treatment of adults (aged 18 years or older) with major depression, identified from the Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS, MEDLINE, PsycINFO, AMED, PSYNDEX, websites of drug licensing agencies and pharmaceutical companies, and trial registries."	2.61	Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. ( Cipriani, A; Cowen, PJ; Egger, M; Furukawa, TA; Leucht, S; Salanti, G, 2019)
"Major depressive disorder is one of the most common mental disorders in children and adolescents."	2.53	Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. ( Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X, 2016)
"Mirtazapine is a commonly used antidepressant with a well-known ability to produce sedation."	2.48	The effects of mirtazapine on sleep in patients with major depressive disorder. ( Dolder, CR; Iler, CA; Nelson, MH, 2012)
"Mirtazapine is an antidepressant with a mechanism that involves activating serotonin (5-HT1) receptors."	2.47	Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. ( Huang, KC; Lee, WK; Li, TC; Shiah, IS; Sun, CJ; Tzang, RF, 2011)
"Mirtazapine has a unique mechanism of antidepressant action, and thus is thought to have a different profile of adverse events from that of other antidepressants."	2.46	Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. ( Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; McGuire, H; Nakagawa, A; Omori, IM; Watanabe, N, 2010)
"The treatment of major depressive disorder requires prolonged pharmacotherapy with antidepressants in order to resolve the current episode and reduce the risk for recurrence of depressive symptoms."	2.46	Improving medication compliance in patients with depression: Use of orodispersible tablets. ( Navarro, V, 2010)
"Mirtazapine-treated patients had a 74% higher likelihood of achieving remission during the first 2 weeks of therapy compared with patients treated with SSRIs."	2.46	Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. ( Nierenberg, AA; Schutte, AJ; Simmons, JH; Thase, ME; van Oers, HJ; Vrijland, P, 2010)
"Mirtazapine is an effective antidepressant with unique and special mechanism of action characterized by high response and remission rates, relatively early onest of action and favourable side-effect profile."	2.45	[Mirtazapine--pharmacologic action and clinical advantages]. ( Purebl, G; Rihmer, Z, 2009)
"Mirtazapine has demonstrated superior tolerability to the tricyclic antidepressants and trazodone, primarily on account of its relative absence of anticholinergic, adrenergic and serotonin-related adverse effects, in particular gastrointestinal adverse effects and sexual dysfunction."	2.40	A risk-benefit assessment of mirtazapine in the treatment of depression. ( Kasper, S; Praschak-Rieder, N; Tauscher, J; Wolf, R, 1997)
" Moreover, previous reviews have not systematically assessed the occurrence of adverse events."	1.91	The risks of adverse events with venlafaxine and mirtazapine versus 'active placebo', placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis. ( Gluud, C; Hengartner, MP; Horowitz, MA; Jakobsen, JC; Juul, S; Jørgensen, CK; Kirsch, I; Moncrieff, J; Munkholm, K; Siddiqui, F, 2023)
"Mirtazapine use was associated with the increased risk of developing hypothyroxinaemia."	1.72	Mirtazapine use may increase the risk of hypothyroxinaemia in patients affected by major depressive disorder. ( Hao, W; Li, M; Retnakaran, R; Wang, N; Wen, SW; Yuan, Y; Zhai, D; Zhang, R; Zhao, Y, 2022)
"The prevalence of major depressive disorder in patients with schizophrenia (SZ-MDD) has been reported to be about 32."	1.72	Electrical stimulus combined with venlafaxine and mirtazapine improves brain Ca ( Cai, Z; Chen, J; Fang, T; Li, Q; Lin, C; Song, X; Tian, H; Yang, L; Zhang, Q; Zhou, C; Zhuo, C, 2022)
"Mirtazapine was restarted at the same dose after 14 days of ongoing symptoms and his symptoms subsided immediately."	1.62	The Hunger for Mirtazapine: A Discontinuation Syndrome. ( Finch, CK; March, KL; McGowan, KE, 2021)
"The widespread prevalence of coronavirus disease 2019 (COVID-19) means that inpatient psychiatric units will necessarily manage patients who have COVID-19 that is comorbid with acute psychiatric symptoms."	1.62	Suspected Recurrence of Symptomatic COVID-19: Management During Inpatient Psychiatric Treatment. ( Frankle, WG; Lequesne, E; Rohs, A; Zhang, E, 2021)
"Our study included 192 patients with major depressive disorder (age - 41."	1.56	The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D6*4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder. ( , 2020)
"Mirtazapine treatment increased N3 sleep at week 1 compared with agomelatine treatment, but this difference disappeared at week 8."	1.56	Effects of agomelatine and mirtazapine on sleep disturbances in major depressive disorder: evidence from polysomnographic and resting-state functional connectivity analyses. ( Bao, YP; Du, LT; Fan, TT; Fu, Y; Gao, XJ; Guo, LH; Hao, XN; Li, LZ; Li, SX; Lin, X; Liu, L; Liu, Z; Lu, L; Mi, WF; Shi, Y; Si, TM; Sun, HQ; Tabarak, S; Wang, L; Wang, XQ; Zhang, HY; Zhang, SZ; Zhang, WH, 2020)
" This chapter will provide an overview of each medication's indication for use, history of development, pharmacology, metabolism, dosing recommendations, onset of action, use in special populations, safety and tolerability, adverse effects, potential interactions with additional medications, and data regarding possible overdose with available treatments."	1.51	Other Antidepressants. ( Macaluso, M; Schwasinger-Schmidt, TE, 2019)
" This case report describes a patient with major depressive disorder, who experienced AAC after the first dosage of mirtazapine treatment, and highlights the importance of close monitoring of individuals under antidepressant treatment particularly immediately after initiation of the drug."	1.42	Mirtazapine-induced acute angle closure. ( Durmaz, O; Durna, MM; Kahraman, N, 2015)
"In 3,455 MDD outpatients with insomnia after treatment, the reduction of sleep latency (P < 0."	1.40	Real-world, open-label study to evaluate the effectiveness of mirtazapine on sleep quality in outpatients with major depressive disorder. ( Hao, W; Li, L; Li, Z; Wang, D, 2014)
"Korean subjects with diagnosis of major depressive disorder using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Axis I disorders were recruited."	1.40	Interaction of 5-HTT and HTR1A gene polymorphisms in treatment responses to mirtazapine in patients with major depressive disorder. ( Cha, JH; Chang, HS; Ham, BJ; Kim, B; Lee, HY; Lee, MS; Won, ES, 2014)
"Besides ketamine, sleep deprivation (SD) as well as partial sleep deprivation (PSD) are effective and fast-acting antidepressant methods."	1.40	Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation. ( Beck, J; Brand, S; Eckert, A; Giese, M; Hatzinger, M; Hemmeter, U; Holsboer-Trachsler, E; Muheim, F, 2014)
"Mirtazapine treatment for 4 weeks significantly increased serum BDNF levels in the responders, whereas nonresponders showed significant decreases."	1.38	Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). ( Atake, K; Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Iwata, N; Katsuki, A; Kishi, T; Nakamura, J; Umene-Nakano, W; Yoshimura, R, 2012)
"Mirtazapine is an antidepressant approved for the treatment of major depressive disorder."	1.38	Antidepressant use in underweight older adults. ( Avena-Woods, C; Hilas, O, 2012)
"Haloperidol was discontinued, but mirtazapine was continued, and the vivid dream activity persisted; however, reality testing when awake was intact."	1.36	Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment. ( Felthous, AR; Hoevet, R; Wenger, PJ, 2010)
" Greater clinical severity and low initial dosing may increase the risk of switching antidepressants."	1.35	Antidepressant switching among adherent patients treated for depression. ( Hassan, M; Marcus, SC; Olfson, M, 2009)
" In 9% of patients, RLS was recorded as a side effect related to the administration of AD."	1.35	Restless legs syndrome as side effect of second generation antidepressants. ( Gallwitz, T; Kirch, MH; Messer, T; Rottach, KG; Schaner, BM; Teufel, LM; Zivotofsky, AZ, 2008)
" The aim of this study was to determine whether in major depression changes in the activity patterns of local modulators of glucocorticoid action might contribute to an increase in cortisol bioavailability and if they change during antidepressant treatment and clinical response."	1.35	Cortisol metabolism in depressed patients and healthy controls. ( Deuschle, M; Frankhauser, P; Gilles, M; Hamann, B; Kopf, D; Lederbogen, F; Lewicka, S; Onken, V; Römer, B; Schilling, C, 2009)
"Treatment with mirtazapine was associated with significant reductions in clinical global impressions-severity of illness scale (CGI-S) score, the Hamilton rating scale for anxiety (HAM-A) total score, the 17-item Hamilton rating scale for depression (HAM-D) total score and the Beck depression inventory (BDI) total scores."	1.34	Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study. ( Doraiswamy, PM; Gersing, K; Hellegers, C; Varia, I; Venkataraman, S, 2007)
"Cannabinoid hyperemesis is a cluster of symptoms characterized by chronic cannabis abuse, cyclical vomiting and compulsive bathing behaviours."	1.34	Cannabinoid hyperemesis: marijuana puts patients in hot water. ( Martin, AL; Park, B; Wallace, D, 2007)
"Mirtazapine was administered for 8 weeks to the 101 MDD patients who completed this study."	1.34	Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression. ( Choi, MJ; Hahn, SW; Kang, RH; Lee, MS, 2007)
"Mirtazapine was administered for eight weeks to the 101 patients who completed the study, during which we evaluated the clinical outcome using repeated-measures ANCOVA."	1.34	Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. ( Choi, MJ; Hahn, SW; Kang, RH; Lee, MS; Paik, JW, 2007)
"Mirtazapine was given in a dose of 30 mg/day for 6 weeks."	1.33	Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients. ( Baccichet, E; Carreira, I; Lima, L; Peña, S; Urbina, M, 2005)
"Mirtazapine has been shown to acutely inhibit cortisol secretion in healthy subjects."	1.32	Influence of mirtazapine on urinary free cortisol excretion in depressed patients. ( Baghai, T; Laakmann, G; Rackwitz, C; Schule, C, 2003)
"Six patients meeting criteria for major depressive disorder and scoring > or =4 on the three Hamilton Depression Rating Scale sleep items were studied."	1.31	Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. ( Bayles-Dazet, W; Gary, KA; Hayes, JB; MacDonald, MM; Sateia, MJ; Winokur, A, 2000)
"Mirtazapine has demonstrated superior tolerability to the tricyclic antidepressants, primarily on account of its relative absence of anticholinergic, adrenergic and serotonin-related adverse effects."	1.31	Occurrence of mirtazapine-induced delirium in organic brain disorder. ( Bailer, U; Fischer, P; Kasper, S; Küfferle, B; Stastny, J, 2000)
"Mirtazapine is a novel antidepressant with a noradrenergic and specific serotonergic mode of action."	1.31	Intravenous mirtazapine in the treatment of depressed inpatients. ( Barnas, C; Hilger, E; Kasper, S; Konstantinidis, A; Neumeister, A; Ptak-Butta, J; Stastny, J; Winkler, D, 2002)
"Mirtazapine is an atypical antidepressant with alpha 2 adrenergic antagonist and serotonin 5-HT2 and 5-HT3 receptor-blocking activity."	1.30	Sexual functioning in depressed outpatients taking mirtazapine. ( Boyarsky, BK; Haque, W; Hirschfeld, RM; Rouleau, MR, 1999)

Research

Studies (238)

Authors

Clinical Trials (19)

Trial Overview

Trial Outcomes

Quality of Life Inventory

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (0.84)	18.2507
2000's	106 (44.54)	29.6817
2010's	97 (40.76)	24.3611
2020's	33 (13.87)	2.80

Authors	Studies
Huang, H	1
Wang, F	2
Chen, Y	1
Kong, S	1
Huang, Q	1
Lyu, D	1
Yang, W	1
Wei, Z	1
Qian, N	1
Zhang, M	1
Wu, C	1
Zhao, J	1
Cao, L	3
Wu, Z	3
Peng, D	2
Fang, Y	3
Hong, W	2
Gulfishan, S	1
Halder, S	1
Kar, R	1
Srivastava, S	1
Gupta, R	2
Iglesias-Escabi, IM	1
Kleesattel, D	1
McDaniel, LS	1
Reuther, E	1
LeBlanc, C	1
Hyman, PE	1
Santucci, NR	1
Ng, E	1
Teshima, J	1
Tan, A	1
Steinberg, R	1
Zhu, A	1
Giacobbe, P	1
Lavan, O	1
Peled, O	1
Avishai-Neumann, M	1
Weizman, A	1
Yahel, A	1
Apter, A	1
Valevski, A	1
Fennig, S	1
Stein, J	1
Benaroya-Milshtein, N	1
Kato, M	4
Ogata, H	2
Tahara, H	2
Shimamoto, A	2
Takekita, Y	4
Koshikawa, Y	4
Nishida, K	3
Nonen, S	2
Higasa, K	2
Kinoshita, T	4
Wu, S	1
Lin, M	1
Rice, T	1
Coffey, BJ	2
Economos, G	1
Alexandre, M	1
Perceau-Chambard, E	1
Villeneuve, L	1
Subtil, F	1
Haesebaert, J	1
Glehen, O	1
Schwalsberger, K	1
Reininghaus, B	1
Reiter, A	1
Dalkner, N	1
Fleischmann, E	1
Fellendorf, F	1
Platzer, M	1
Reininghaus, EZ	1
Naito, M	1
Bandou, H	2
Sakai, S	2
He, S	1
Ikner, TP	1
Taylor, BV	1
Aguiar, T	1
Thakur, NP	1
Chakravorty, S	1
Zhuo, C	1
Zhou, C	1
Cai, Z	1
Chen, J	3
Yang, L	3
Li, Q	1
Zhang, Q	1
Fang, T	1
Tian, H	1
Lin, C	1
Song, X	1
Kishi, T	2
Ikuta, T	1
Sakuma, K	1
Okuya, M	1
Hatano, M	1
Matsuda, Y	2
Iwata, N	2
Oravecz, R	1
Stuhec, M	1
Jørgensen, CK	1
Juul, S	1
Siddiqui, F	1
Horowitz, MA	1
Moncrieff, J	1
Munkholm, K	1
Hengartner, MP	1
Kirsch, I	1
Gluud, C	1
Jakobsen, JC	1
Vita, G	1
Compri, B	1
Matcham, F	1
Barbui, C	3
Ostuzzi, G	1
Kageyama, Y	1
Kato, T	3
Østergaard, SD	1
Hirakawa, H	1
Burchi, E	1
Fava, M	8
Chen, C	1
Shan, W	1
Furukawa, TA	8
Salanti, G	2
Cowen, PJ	2
Leucht, S	4
Cipriani, A	6
Xiao, L	2
Zhu, X	1
Gillespie, A	1
Feng, Y	2
Zhou, J	1
Chen, X	1
Gao, Y	1
Wang, X	3
Ma, X	1
Gao, C	1
Xie, Y	1
Pan, X	1
Bai, Y	1
Xu, X	1
Wang, G	2
Chen, R	2
Furukawa, Y	1
Yamazaki, R	1
Inamura, K	1
Kito, S	1
Nunomura, A	1
Shigeta, M	1
Salisbury-Afshar, E	1
Ozdemir, F	1
Dural, E	1
Baskak, NS	1
Kır, Y	1
Baskak, B	1
Suzen, HS	1
Mi, WF	1
Tabarak, S	1
Wang, L	1
Zhang, SZ	1
Lin, X	1
Du, LT	1
Liu, Z	1
Bao, YP	1
Gao, XJ	1
Zhang, WH	1
Wang, XQ	1
Fan, TT	1
Li, LZ	1
Hao, XN	1
Fu, Y	1
Shi, Y	1
Guo, LH	1
Sun, HQ	1
Liu, L	2
Si, TM	1
Zhang, HY	1
Lu, L	1
Li, SX	1
Berger, M	1
Li, E	1
Amminger, GP	1
Woo, HI	2
Park, J	1
Lim, SW	2
Kim, DK	2
Lee, SY	4
Zhang, E	1
Lequesne, E	1
Rohs, A	1
Frankle, WG	1
Wang, Y	3
Su, Y	1
Huang, J	1
Fang, M	1
Yao, Z	1
Wang, Z	1
Zhu, Y	1
McGowan, KE	1
March, KL	1
Finch, CK	1
Hetrick, SE	2
McKenzie, JE	1
Bailey, AP	1
Sharma, V	1
Moller, CI	1
Badcock, PB	1
Cox, GR	1
Merry, SN	1
Meader, N	1
Zhao, Y	1
Wang, N	1
Wen, SW	1
Li, M	1
Yuan, Y	1
Retnakaran, R	1
Hao, W	2
Zhang, R	1
Zhai, D	1
Leung, SM	1
Jha, MK	3
Minhajuddin, A	3
Gadad, BS	1
Greer, TL	2
Mayes, TL	1
Trivedi, MH	14
Na, KS	1
Jung, HY	1
Cho, SJ	1
Cho, SE	1
Navarro Dávila, MA	1
Shihadeh, LA	1
Plasencia García, I	1
Fennema, H	1
Engel, RR	1
Kaspers-Janssen, M	1
Szegedi, A	8
Wakhlu, S	1
Dronamraju, N	1
Myung, W	1
Lopes, R	1
Melo, R	1
Dias Pereira, B	1
Schwasinger-Schmidt, TE	1
Macaluso, M	1
Jaffe, RJ	2
Juneja, NS	2
Hairston, DR	1
de Similien, RH	1
Himelhoch, S	1
Forrester, A	1
De La Garza, N	1
Rush, AJ	11
Killian, MO	1
Grannemann, BD	1
Carmody, TJ	1
Mirza, T	1
Majeed, MH	1
Noma, H	1
Maruo, K	1
Imai, H	1
Shinohara, K	2
Tanaka, S	2
Ikeda, K	1
Yamawaki, S	1
South, C	1
Egger, M	1
Hieronymus, F	1
Chen, HM	1
Yang, YH	1
Chen, KJ	1
Lee, Y	1
McIntyre, RS	1
Lu, ML	1
Lee, YC	1
Hsieh, MC	1
Chen, VC	1
Schroeder, K	1
Huber, CG	1
Jahn, H	1
Waltereit, R	1
Eifler, S	1
Schirmbeck, F	1
Zink, M	2
Wang, D	1
Li, Z	1
Li, L	1
Bognár, Z	1
Vonyik, G	1
Gazdag, G	1
Raddin, RS	1
Park, EM	1
Hamer, RM	1
Nelson, KM	1
Mayer, DK	1
Rosenstein, DL	1
Bernard, SA	1
Ng, CG	1
Boks, MP	1
Roes, KC	1
Zainal, NZ	1
Sulaiman, AH	1
Tan, SB	1
de Wit, NJ	1
Warden, D	5
Carmody, T	1
Toups, M	1
Zisook, S	4
Lesser, I	1
Myers, A	1
Kurian, KR	1
Morris, D	1
Chang, HS	5
Lee, HY	5
Cha, JH	1
Won, ES	2
Ham, BJ	4
Kim, B	1
Lee, MS	9
Tak, S	2
Muguruza, C	1
Miranda-Azpiazu, P	1
Díez-Alarcia, R	1
Morentin, B	1
González-Maeso, J	1
Callado, LF	1
Meana, JJ	1
Giese, M	1
Beck, J	1
Brand, S	1
Muheim, F	1
Hemmeter, U	1
Hatzinger, M	1
Holsboer-Trachsler, E	1
Eckert, A	1
Kim, YG	1
Gronau, W	2
Paslakis, G	1
Lederbogen, F	8
Weber-Hamann, B	6
Gilles, M	8
Schilling, C	6
Deuschle, M	8
Alampay, MM	1
Haigney, MC	1
Flanagan, MC	1
Perito, RM	1
Love, KM	1
Grammer, GG	1
Sung, SC	3
Wisniewski, SR	8
Luther, JF	4
Helmreich, I	1
Wagner, S	1
König, J	1
Kohnen, R	5
Hiemke, C	1
Tadić, A	4
Ueno, F	1
Nakajima, S	2
Suzuki, T	2
Abe, T	1
Sato, Y	1
Mimura, M	2
Uchida, H	2
Schmidt, FM	2
Nowak, C	1
Kratzsch, J	1
Sander, C	1
Hegerl, U	1
Schönknecht, P	1
Won, E	1
Kahraman, N	1
Durmaz, O	1
Durna, MM	1
Guo, T	1
Xiang, YT	2
Hu, CQ	1
Chiu, HF	1
Ungvari, GS	1
Correll, CU	1
Lai, KY	1
Feng, L	1
Geng, Y	1
Yonemoto, N	3
Mantani, A	1
Ogawa, Y	1
Tajika, A	1
Takeshima, N	1
Hayasaka, Y	1
Miki, K	3
Inagaki, M	3
Shimodera, S	3
Akechi, T	3
Yamada, M	3
Watanabe, N	5
Guyatt, GH	1
Messer, T	2
Funaki, K	1
Gupta, K	1
Tripathi, AK	1
Bhatia, MS	1
Gupta, LK	1
Rzezniczek, S	1
Obuchowicz, M	1
Datka, W	1
Siwek, M	1
Dudek, D	1
Kmiotek, K	1
Oved, K	1
Shomron, N	1
Gurwitz, D	1
Pilc, A	1
Zhou, X	1
Del Giovane, C	1
Qin, B	1
Whittington, C	1
Coghill, D	1
Zhang, Y	1
Hazell, P	1
Cuijpers, P	1
Pu, J	1
Cohen, D	1
Ravindran, AV	1
Liu, Y	1
Michael, KD	1
Xie, P	1
Cornelius, JR	1
Chung, T	1
Douaihy, AB	1
Kirisci, L	1
Glance, J	1
Kmiec, J	1
FitzGerald, D	1
Wesesky, MA	1
Salloum, I	1
Zheng, W	1
Zhang, YF	1
Zhong, HQ	1
Mai, SM	1
Yang, XH	1
Sunada, N	1
Onohara, A	1
Hatashita, Y	1
Serretti, A	1
Chekroud, AM	1
Gueorguieva, R	1
Krumholz, HM	1
Krystal, JH	1
McCarthy, G	1
Yoshino, Y	1
Ochi, S	1
Yamazaki, K	1
Nakata, S	1
Iga, JI	1
Ueno, SI	1
Gourion, D	1
Liu, CC	1
Liang, KY	1
Liao, SC	1
Schüle, C	10
Baghai, TC	5
Eser, D	5
Nothdurfter, C	2
Rupprecht, R	7
Onken, V	4
Frankhauser, P	4
Kopf, D	6
Ladeira, RB	1
Cunha, FT	1
Salgado, JV	1
Teixeira, AL	1
Nicolato, R	1
Lopes, J	1
Goyal, N	1
Sinha, VK	1
Blier, P	3
Seo, HJ	1
Jung, YE	2
Woo, YS	1
Jun, TY	2
Chae, JH	2
Bahk, WM	2
Shen, J	2
Moller, HJ	5
Chung, SA	2
Shapiro, GK	1
Li, X	1
Shapiro, CM	2
Omori, IM	2
Nakagawa, A	2
McGuire, H	2
Churchill, R	2
Jansen, WT	1
van Willigenburg, AP	1
van der Meulen, E	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
What is the Effectiveness and Safety of Mirtazapine Versus Escitalopram in Alleviating Cancer-associated Poly-symptomatology (MIR-P)? A Mixed-method Randomized Controlled Trial Protocol[NCT04763135]	Phase 3	1 participants (Actual)	Interventional	2021-12-15	Terminated (stopped due to difficulties in recruiting)
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640]	Phase 1/Phase 2	520 participants (Anticipated)	Interventional	2023-02-20	Recruiting
Combining Medications to Enhance Depression Outcomes[NCT00590863]	Phase 4	665 participants (Actual)	Interventional	2008-03-31	Completed
Observational Longitudinal Study of Individuals With Stimulant Use Disorder: Research and Development of a Biosignature[NCT06073340]		1,500 participants (Anticipated)	Observational	2023-11-16	Recruiting
Suicide Assessment Methodology Study (SAMS)[NCT00532103]		300 participants (Anticipated)	Observational	2007-07-31	Completed
A Parallel-group, Double-blind, Placebo-controlled Study of Methylphenidate as an Add on Therapy for Mirtazapine in the Treatment of Major Depressive Disorder in Cancer Patients Under Palliative Care[NCT01497548]	Phase 3	120 participants (Anticipated)	Interventional	2011-03-31	Recruiting
Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder[NCT05357040]	Phase 2	172 participants (Anticipated)	Interventional	2021-06-30	Recruiting
Digital Interventions as an Add-on Tool in Generalized Anxiety Disorder Treatment: A Randomized Clinical Trial[NCT05375851]		60 participants (Anticipated)	Interventional	2022-05-01	Recruiting
Strategic Use of New Generation Antidepressants for Depression[NCT01109693]	Phase 4	2,011 participants (Actual)	Interventional	2010-12-31	Completed
Development and Evaluation of an Ecological Momentary Assessment (EMA) Baseline Screening System for Therapists Who Treat Youths With Depressive Symptoms[NCT04830527]		60 participants (Actual)	Interventional	2020-11-24	Terminated (stopped due to The study was terminated early due to the difficulty in recruiting cases during a pandemic period.)
Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.[NCT02185131]	Phase 2	16 participants (Actual)	Interventional	2013-09-30	Completed
Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial[NCT02646449]	Phase 2	11 participants (Actual)	Interventional	2015-06-30	Completed
Antidepressant Response to a Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder[NCT00385437]	Phase 2	16 participants	Interventional	2003-04-30	Completed
THE AIUNI - Integral Assessment in Unipolar Depression[NCT02268487]	Phase 4	100 participants (Anticipated)	Interventional	2014-01-31	Recruiting
Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder[NCT03230682]		80 participants (Anticipated)	Observational [Patient Registry]	2017-07-25	Recruiting
Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544]	Phase 2	236 participants (Anticipated)	Interventional	2015-12-31	Active, not recruiting
Sequenced Treatment Alternatives to Relieve Depression[NCT00021528]	Phase 4	4,000 participants	Interventional	2001-07-31	Completed
Evaluation of Blended Stepped-care Mental Well-being Intervention for Adults: A Randomized Controlled Trial[NCT05395312]		402 participants (Anticipated)	Interventional	2022-07-30	Active, not recruiting
Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine[NCT01075529]	Phase 4	140 participants (Actual)	Interventional	2007-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7

Quick Inventory of Depressive Symptoms

Intervention	units on a scale (Mean)
Escitalopram + Bupropion SR	0.6
Venlafaxine XR + Mirtazapine	0.4
Escitalopram + Placebo	0.4

Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7

Drinks Per Drinking Day

Intervention	percentage of participants (Number)
Escitalopram + Bupropion SR	46.6
Venlafaxine XR + Mirtazapine	41.8
Escitalopram + Placebo	46.0

Level of drinking, as indicated by the number of drinks per day as recorded on the Timeline Follow-Back calendar. (NCT02185131)
Timeframe: 12 Weeks

Level of Depressive Symptoms

Intervention	Drinks per drinking day (Mean)
Mirtazapine	3.5
Placebo	4.4

Level of depressive symptoms, as indicated by the score on the Beck Depression Inventory. The Beck Depression Inventory II scoring range is as follows: 0-13 minimal depressive symptoms, 14-19 mild depressive symptoms, 20-28 moderate depressive symptoms and 29-63 severe depressive symptoms. (NCT02185131)
Timeframe: 12 Weeks

Drinks Per Drinking Day

Intervention	Units on a scale (Mean)
Mirtazapine	27.6
Placebo	26.1

Level of drinking, as indicated by the number of drinks per day as recorded on the Timeline Follow-Back calendar. (NCT02646449)
Timeframe: 12 Weeks

Level of Depressive Symptoms

Article	Year
Psychopharmacology in the Pediatric Oncology and Bone Marrow Transplant Units: Antidepressant Treatment. Journal of child and adolescent psychopharmacology, 2022, Volume: 32, Issue:3 Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Humans; Mirtazapine; Neoplasms	2022
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Molecular psychiatry, 2023, Volume: 28, Issue:1 Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine	2023
Bupropion XL unapproved use in the prisons: Two cases focused on the bupropion pharmacology. Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata, 2022, Volume: 37, Issue:3 Topics: Adult; Aripiprazole; Bupropion; Depressive Disorder, Major; Dopamine; Humans; Mirtazapine; Norepinep	2022
Antidepressants for the treatment of depression in people with cancer. The Cochrane database of systematic reviews, 2023, 03-31, Volume: 3 Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Depressive Disorder, Maj	2023
Pharmacological and non-pharmacological treatments for major depressive disorder in adults: A systematic review and network meta-analysis. Psychiatry research, 2019, Volume: 281 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral The	2019
No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review. Acta psychiatrica Scandinavica, 2020, Volume: 141, Issue:5 Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female;	2020
Adverse Events of Pharmacologic Treatments of Major Depression in Older Adults. American family physician, 2020, 02-01, Volume: 101, Issue:3 Topics: Aged; Bupropion; Depressive Disorder, Major; Female; Humans; Male; Mirtazapine; Randomized Controlle	2020
New generation antidepressants for depression in children and adolescents: a network meta-analysis. The Cochrane database of systematic reviews, 2021, 05-24, Volume: 5 Topics: Adolescent; Antidepressive Agents; Bias; Child; Citalopram; Depressive Disorder, Major; Desvenlafaxi	2021
Can we recommend mirtazapine and bupropion for patients at risk for bleeding?: A systematic review and meta-analysis. Journal of affective disorders, 2018, 01-01, Volume: 225 Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Databases, Fa	2018
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. Journal of affective disorders, 2019, 05-01, Volume: 250 Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disor	2019
Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. The lancet. Psychiatry, 2019, Volume: 6, Issue:7 Topics: Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Mirtazapi	2019
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet (London, England), 2016, Aug-27, Volume: 388, Issue:10047 Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co	2016
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet (London, England), 2016, Aug-27, Volume: 388, Issue:10047 Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co	2016
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet (London, England), 2016, Aug-27, Volume: 388, Issue:10047 Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co	2016
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet (London, England), 2016, Aug-27, Volume: 388, Issue:10047 Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co	2016
Wuling Capsule for Major Depressive Disorder: A Meta-analysis of Randomised Controlled Trials. East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, 2016, Volume: 26, Issue:3 Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents,	2016
[Antidepressants and their onset of action: a major clinical, methodological and pronostical issue]. L'Encephale, 2008, Volume: 34, Issue:1 Topics: Affect; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Duloxetine Hyd	2008
Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:9 Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Humans; Mianserin; Mirtazapine; Random	2008
Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:3 Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Mianserin; Mirt	2009
Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:3 Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Mianserin; Mirt	2009
Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:3 Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Mianserin; Mirt	2009
Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:3 Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Mianserin; Mirt	2009
Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS drugs, 2009, Volume: 23, Issue:5 Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Databases, Bibliographic; Depressive Disorder,	2009
[Mirtazapine--pharmacologic action and clinical advantages]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2009, Volume: 11, Issue:1 Topics: Adrenergic alpha-Antagonists; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Depress	2009
Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS drugs, 2010, Volume: 24, Issue:1 Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Tricyclic; Depressive Disorde	2010
Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. International clinical psychopharmacology, 2010, Volume: 25, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive	2010
Improving medication compliance in patients with depression: Use of orodispersible tablets. Advances in therapy, 2010, Volume: 27, Issue:11 Topics: Administration, Oral; Antidepressive Agents; Citalopram; Deglutition Disorders; Depressive Disorder,	2010
Therapeutic potential of new second generation antipsychotics for major depressive disorder. Expert opinion on investigational drugs, 2010, Volume: 19, Issue:12 Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Depressive Di	2010
Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. The journal of ECT, 2011, Volume: 27, Issue:2 Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Electroconvulsive Therapy; Fema	2011
Antidepressant combination for major depression in incomplete responders--a systematic review. Journal of affective disorders, 2013, Jan-10, Volume: 144, Issue:1-2 Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug The	2013
The effects of mirtazapine on sleep in patients with major depressive disorder. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2012, Volume: 24, Issue:3 Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Humans; Mianserin; Mirtazapine; Random	2012
Dual action antidepressants and some important considerations. The Australian and New Zealand journal of psychiatry, 2003, Volume: 37, Issue:2 Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Second-Generation; Cyclohexanols; Cyclopropanes	2003
Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. International clinical psychopharmacology, 2005, Volume: 20, Issue:2 Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder, Major; Huma	2005
[Review of antidepressants from the TCAs to the third generation drugs]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2004, Volume: 6, Issue:4 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; B	2004
Mirtazapine: a review of its clinical efficacy and tolerability. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:4 Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Mental Disorder	2005
Major depressive disorder, antidepressants, and sexual dysfunction. The Journal of clinical psychiatry, 2006, Volume: 67 Suppl 6 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; B	2006
Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biological psychiatry, 2008, Apr-01, Volume: 63, Issue:7 Topics: Bupropion; Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Humans; Mianserin; Mirtazapin	2008
A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:8 Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Mianserin; Mirtazapine; Randomized Contro	2008
A risk-benefit assessment of mirtazapine in the treatment of depression. Drug safety, 1997, Volume: 17, Issue:4 Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depression; Depressive Disorder; Depressive Disorder,	1997
Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. The international journal of neuropsychopharmacology, 2001, Volume: 4, Issue:4 Topics: Adult; Affect; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Res	2001

Article	Year
Difference in the regulation of biological rhythm symptoms of Major depressive disorder between escitalopram and mirtazapine. Journal of affective disorders, 2022, 01-01, Volume: 296 Topics: Circadian Rhythm; Citalopram; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans;	2022
Association of serotonin transporter gene polymorphism with efficacy of the antidepressant drugs sertraline and mirtazapine in newly diagnosed patients with major depressive disorders. Human psychopharmacology, 2022, Volume: 37, Issue:4 Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Mirtazapine; Polymorphism, Genetic; Selec	2022
Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways. International journal of molecular sciences, 2022, Mar-31, Volume: 23, Issue:7 Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; MicroRNAs; Mirtazapine; Selective Seroton	2022
What is the effectiveness and safety of mirtazapine versus escitalopram in alleviating cancer-associated poly-symptomatology (the MIR-P study)? A mixed-method randomized controlled trial protocol. BMC palliative care, 2022, May-23, Volume: 21, Issue:1 Topics: Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Humans; Mirtazapine; Neoplasms; Pro	2022
Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8 weeks. Journal of affective disorders, 2022, 10-01, Volume: 314 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Mirtazapine; Outcome Assessme	2022
Relationship between circulating mitochondrial DNA and microRNA in patients with major depression. Journal of affective disorders, 2023, 10-15, Volume: 339 Topics: Cell-Free Nucleic Acids; Depression; Depressive Disorder, Major; DNA, Mitochondrial; Humans; MicroRN	2023
Effectiveness of mirtazapine as add-on to paroxetine Psychological medicine, 2021, Volume: 51, Issue:7 Topics: Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; China; Depressiv	2021
Predictors and moderators of quality of life in patients with major depressive disorder: An AGTs-MDD study report. Journal of psychiatric research, 2021, Volume: 138 Topics: Citalopram; Depressive Disorder, Major; Female; Humans; Male; Mirtazapine; Quality of Life; Suicidal	2021
Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial. Journal of affective disorders, 2018, Volume: 234 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Biomarkers; Body	2018
The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. Depression and anxiety, 2019, Volume: 36, Issue:4 Topics: Adult; Aged; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Drug Therapy, Combinatio	2019
Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014, Volume: 24, Issue:4 Topics: Academic Medical Centers; Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and St	2014
Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care. Journal of psychiatric practice, 2014, Volume: 20, Issue:2 Topics: Adult; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive Diso	2014
Increased platelet count after treatment with venlafaxine or mirtazapine in depressed patients. Pharmacopsychiatry, 2015, Volume: 48, Issue:1 Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major;	2015
Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. Journal of affective disorders, 2015, Mar-15, Volume: 174 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Citalopram; Comorbidit	2015
Hamilton depression rating subscales to predict antidepressant treatment outcome in the early course of treatment. Journal of affective disorders, 2015, Apr-01, Volume: 175 Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Mianse	2015
Whether to increase or maintain dosage of mirtazapine in early nonimprovers with depression. The Journal of clinical psychiatry, 2015, Volume: 76, Issue:4 Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Response Relationshi	2015
Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters. The American journal of psychiatry, 2015, Volume: 172, Issue:10 Topics: Adult; Antidepressive Agents; Clinical Decision-Making; Depressive Disorder, Major; Female; Humans;	2015
Strategic use of new generation antidepressants for depression: SUN(^_^) D protocol update and statistical analysis plan. Trials, 2015, Oct-14, Volume: 16 Topics: Antidepressive Agents, Tricyclic; Clinical Protocols; Data Interpretation, Statistical; Depressive D	2015
Early Improvements in Individual Symptoms to Predict Later Remission in Major Depressive Disorder Treated With Mirtazapine. Journal of clinical pharmacology, 2016, Volume: 56, Issue:9 Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-Blind Method; Fema	2016
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial. Psychiatry research, 2016, Aug-30, Volume: 242 Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression;	2016
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial. Psychiatry research, 2016, Aug-30, Volume: 242 Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression;	2016
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial. Psychiatry research, 2016, Aug-30, Volume: 242 Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression;	2016
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial. Psychiatry research, 2016, Aug-30, Volume: 242 Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression;	2016
Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. Journal of psychiatric research, 2017, Volume: 89 Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Drug Therapy, Combination; Female; F	2017
Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: an open-label study. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:4 Pt 2 Topics: Adult; Aged; Anticonvulsants; Antidepressive Agents, Tricyclic; Antimanic Agents; Biological Availab	2009
Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting. Human psychopharmacology, 2009, Volume: 24, Issue:2 Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Cyclohexanols; Depressive	2009
Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:3 Topics: Accidents, Traffic; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tr	2009
Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2009, Volume: 19, Issue:7 Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyc	2009
Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:12 Topics: Antidepressive Agents, Tricyclic; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Gen	2010
Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial. Psychiatry research, 2009, Sep-30, Volume: 169, Issue:2 Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyc	2009
Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. The American journal of psychiatry, 2010, Volume: 167, Issue:3 Topics: Adult; Antidepressive Agents; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met	2010
Venlafaxine, but not mirtazapine lowers retinol-binding protein 4 serum concentrations in nondiabetic depressed patients. Psychotherapy and psychosomatics, 2010, Volume: 79, Issue:2 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cross-Secti	2010
Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2010, Volume: 11, Issue:1 Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Diagnostic and Statistical Manu	2010
Mirtazapine does not influence tetrahydrodeoxycorticosterone levels in depressed patients. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2010, Volume: 11, Issue:2 Pt 2 Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Desoxycorticosterone; Fem	2010
Antidepressant treatment with mirtazapine, but not venlafaxine, lowers cortisol concentrations in saliva: a randomised open trial. Psychiatry research, 2010, May-15, Volume: 177, Issue:1-2 Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Circadian Rhythm; Cyclohexanols; Depressiv	2010
Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; China; Cyclohexan	2010
Different effects of mirtazapine and venlafaxine on brain activation: an open randomized controlled fMRI study. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Basal Ganglia; Br	2011
Neural correlates of treatment outcome in major depression. The international journal of neuropsychopharmacology, 2011, Volume: 14, Issue:4 Topics: Adult; Affect; Antidepressive Agents; Biomarkers; Cerebral Cortex; Cyclohexanols; Depressive Disorde	2011
Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:7 Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Apolipoprotein A-I; Apolipop	2011
Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. International journal of clinical practice, 2011, Volume: 65, Issue:3 Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxie	2011
Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. Trials, 2011, May-11, Volume: 12 Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cluster Analysis; Depressive D	2011
Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:10 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Citalopram; Cyclohexanols; Delayed-Action	2011
Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. Depression and anxiety, 2012, Volume: 29, Issue:2 Topics: Adolescent; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive	2012
The first 100 patients in the SUN(^_^)D trial (strategic use of new generation antidepressants for depression): examination of feasibility and adherence during the pilot phase. Trials, 2012, Jun-08, Volume: 13 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Ma	2012
The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:7 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Comorbidity;	2012
Treatment with mirtazapine and venlafaxine increases noradrenaline excretion in depressed patients. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; De	2012
Effects of mirtazapine on the sleep wake rhythm of geriatric patients with major depression: an exploratory study with actigraphy. Pharmacopsychiatry, 2013, Volume: 46, Issue:2 Topics: Actigraphy; Age Factors; Aged; Aged, 80 and over; Depressive Disorder, Major; Female; Humans; Male;	2013
Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:5 Topics: Adult; Age Factors; Aged; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP1A2; Cytochrome P-45	2012
Changes of serum concentrations of brain-derived neurotrophic factor (BDNF) during treatment with venlafaxine and mirtazapine: role of medication and response to treatment. Pharmacopsychiatry, 2013, Volume: 46, Issue:2 Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cyclohexanols; Depressive Disorder, Major;	2013
Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. Psychological medicine, 2013, Volume: 43, Issue:5 Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Bupropion; Child Ab	2013
Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of psychosomatic research, 2013, Volume: 74, Issue:1 Topics: Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Fo	2013
Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry, 2002, Volume: 35, Issue:6 Topics: Adult; Aged; Antipsychotic Agents; Body Mass Index; Body Weight; Cross-Over Studies; Cyclohexanols;	2002
Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. Psychopharmacology, 2003, Volume: 166, Issue:3 Topics: Adrenocorticotropic Hormone; Adult; Antidepressive Agents, Tricyclic; Corticotropin-Releasing Hormon	2003
Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology, 2002, Volume: 46, Issue:4 Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; F	2002
Influence of mirtazapine on salivary cortisol in depressed patients. Neuropsychobiology, 2003, Volume: 47, Issue:1 Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; F	2003
Substance P serum levels are increased in major depression: preliminary results. Biological psychiatry, 2003, Mar-15, Volume: 53, Issue:6 Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Diagnostic and Statistica	2003
Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. The Journal of clinical psychiatry, 2003, Volume: 64, Issue:10 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disord	2003
Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy & behavior : E&B, 2003, Volume: 4, Issue:6 Topics: Adult; Aged; Analysis of Variance; Anticonvulsants; Antidepressive Agents; Chi-Square Distribution;	2003
Reboxetine adjunct for partial or nonresponders to antidepressant treatment. Journal of affective disorders, 2004, Volume: 81, Issue:1 Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Drug R	2004
Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. Journal of child and adolescent psychopharmacology, 2004,Summer, Volume: 14, Issue:2 Topics: Adolescent; Antidepressive Agents, Tricyclic; Child; Depressive Disorder, Major; Female; Humans; Mal	2004
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Archives of general psychiatry, 2004, Volume: 61, Issue:11 Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Depressive Disorder, Major; Female; Genetic Mar	2004
Mirtazapine acutely inhibits salivary cortisol concentrations in depressed patients. Annals of the New York Academy of Sciences, 2004, Volume: 1032 Topics: Adrenocorticotropic Hormone; Adult; Antidepressive Agents, Tricyclic; Area Under Curve; Depressive D	2004
Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. Journal of clinical pharmacy and therapeutics, 2005, Volume: 30, Issue:2 Topics: Adolescent; Adult; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders	2005
Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study. Therapeutic drug monitoring, 2005, Volume: 27, Issue:4 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents,	2005
Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed? Psychopharmacology, 2005, Volume: 181, Issue:3 Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Response Relationshi	2005
Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepress	2006
Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2006, Volume: 51, Issue:1 Topics: Adult; Affect; Antidepressive Agents, Tricyclic; Body Weight; Depressive Disorder, Major; Drug Admin	2006
Intravenous mirtazapine is safe and effective in the treatment of depressed inpatients. Neuropsychobiology, 2006, Volume: 53, Issue:2 Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Fatigue; Fema	2006
Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients. Psychopharmacology, 2006, Volume: 186, Issue:4 Topics: Adrenocorticotropic Hormone; Adult; Aged; Antidepressive Agents; Corticotropin-Releasing Hormone; De	2006
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STARD report. The American journal of psychiatry, 2006, Volume: 163, Issue:7* Topics: Adult; Ambulatory Care; Antidepressive Agents, Tricyclic; Bupropion; Citalopram; Cross-Over Studies;	2006
Keeping our eyes on STARD. The American journal of psychiatry, 2006, Volume: 163, Issue:9* Topics: Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; H	2006
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STARD report. The American journal of psychiatry, 2006, Volume: 163, Issue:9* Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricy	2006
The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2007, Apr-05, Volume: 144B, Issue:3 Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Gene Frequenc	2007
Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:11 Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combinati	2006
Mirtazapine-associated dose-dependent and asymptomatic elevation of hepatic enzymes. The Annals of pharmacotherapy, 2007, Volume: 41, Issue:2 Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Response Relationship, Dru	2007
Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2007, Volume: 8, Issue:2 Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Bipolar Disorder;	2007
Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Progress in neuro-psychopharmacology & biological psychiatry, 2007, Aug-15, Volume: 31, Issue:6 Topics: Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Chi-Square Distribution; Depressive D	2007
A monoamine oxidase B gene variant and short-term antidepressant treatment response. Progress in neuro-psychopharmacology & biological psychiatry, 2007, Oct-01, Volume: 31, Issue:7 Topics: Adult; Alleles; Antidepressive Agents; Data Interpretation, Statistical; Depressive Disorder, Major;	2007
Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Human psychopharmacology, 2008, Volume: 23, Issue:4 Topics: Adult; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middl	2008
Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry and clinical neurosciences, 2008, Volume: 62, Issue:1 Topics: Adjustment Disorders; Administration, Oral; Adult; Aged; Antidepressive Agents, Tricyclic; Depressiv	2008
Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2008, Volume: 16, Issue:11 Topics: Adaptation, Psychological; Adjustment Disorders; Adrenergic alpha-Antagonists; Adult; Antidepressive	2008
Mirtazapine for depression in patients with human immunodeficiency virus. Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:2 Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; HIV Seropositivity; Hum	2000
Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:10 Topics: Adult; Chronic Disease; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies;	2001
A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biological psychiatry, 2002, Jan-15, Volume: 51, Issue:2 Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-B	2002

Article	Year
Effect of Mirtazapine on Nausea in Children with Functional Nausea and Functional Dyspepsia Postprandial Distress Syndrome. Paediatric drugs, 2022, Volume: 24, Issue:2 Topics: Adolescent; Adult; Child; Depressive Disorder, Major; Dyspepsia; Female; Humans; Mirtazapine; Nausea	2022
Senior Residents' Perceived Competence in Evidence-Based Treatments for Major Depressive Disorder. Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry, 2022, Volume: 46, Issue:6 Topics: Canada; Clinical Competence; Depressive Disorder, Major; Humans; Internship and Residency; Mirtazapi	2022
Case Report: When Time is of the Essence-Benefits of Mirtazapine in an Adolescent with Major Depressive Disorder and Insomnia, Suicidal Thoughts, and Catatonic Features. Journal of child and adolescent psychopharmacology, 2022, Volume: 32, Issue:3 Topics: Adolescent; Depression; Depressive Disorder, Major; Humans; Mirtazapine; Sleep Initiation and Mainte	2022
Sex-Related Differences in the Pharmacological Treatment of Major Depression - Are Women and Men Treated Differently? Psychiatria Danubina, 2022,Summer, Volume: 34, Issue:2 Topics: Bupropion; Depression; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions;	2022
Mirtazapine-associated acute pancreatitis in a patient with insomnia and co-occurring psychiatric disorders. Journal of the National Medical Association, 2022, Volume: 114, Issue:6 Topics: Acute Disease; Depressive Disorder, Major; Female; Humans; Middle Aged; Mirtazapine; Pancreatitis	2022
Electrical stimulus combined with venlafaxine and mirtazapine improves brain Ca Journal of affective disorders, 2022, 12-15, Volume: 319 Topics: Animals; Clozapine; Depressive Disorder, Major; Humans; Mice; Mirtazapine; Prefrontal Cortex; Schizo	2022
The risks of adverse events with venlafaxine and mirtazapine versus 'active placebo', placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis. Systematic reviews, 2023, 03-30, Volume: 12, Issue:1 Topics: Adult; Depressive Disorder, Major; Humans; Meta-Analysis as Topic; Mirtazapine; Quality of Life; Rev	2023
Optimal dosing of antidepressant drugs. The lancet. Psychiatry, 2019, Volume: 6, Issue:10 Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Mirtazapine; Selective Serotonin Reuptake	2019
Optimal dosing of antidepressant drugs. The lancet. Psychiatry, 2019, Volume: 6, Issue:10 Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Mirtazapine; Selective Serotonin Reuptake	2019
Optimal dosing of antidepressant drugs. The lancet. Psychiatry, 2019, Volume: 6, Issue:10 Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Mirtazapine; Selective Serotonin Reuptake	2019
Mirtazapine-induced long QT syndrome in an elderly patient: a case report. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2020, Volume: 20, Issue:4 Topics: Age Factors; Aged, 80 and over; Antidepressive Agents; Depression; Depressive Disorder, Major; Elect	2020
The Association of Combinatorial chemistry & high throughput screening, 2020, Volume: 23, Issue:10 Topics: Adult; Anxiety Disorders; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Female; Genotype; Hum	2020
Effects of agomelatine and mirtazapine on sleep disturbances in major depressive disorder: evidence from polysomnographic and resting-state functional connectivity analyses. Sleep, 2020, 11-12, Volume: 43, Issue:11 Topics: Acetamides; Depressive Disorder, Major; Double-Blind Method; Humans; Mirtazapine; Sleep; Treatment O	2020
The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D64 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder. Psychopharmacology bulletin, 2020, 07-23, Volume: 50, Issue:3* Topics: Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Humans; MicroRNAs; Mirtazapine; Tandem Mass Spe	2020
Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. BMJ case reports, 2020, Oct-07, Volume: 13, Issue:10 Topics: Adult; Cannabidiol; Cognitive Behavioral Therapy; Depressive Disorder, Major; Depressive Disorder, T	2020
Alteration of transthyretin and thyroxine-binding globulin in major depressive disorder: multiple reaction monitoring-based proteomic analysis. Journal of translational medicine, 2021, 01-15, Volume: 19, Issue:1 Topics: Depressive Disorder, Major; Humans; Mirtazapine; Prealbumin; Proteomics; Thyroxine-Binding Globulin	2021
Suspected Recurrence of Symptomatic COVID-19: Management During Inpatient Psychiatric Treatment. Journal of psychiatric practice, 2021, Mar-05, Volume: 27, Issue:2 Topics: Adult; Alcoholism; Antidepressive Agents; Antipsychotic Agents; Clozapine; COVID-19; COVID-19 Nuclei	2021
The Hunger for Mirtazapine: A Discontinuation Syndrome. Journal of pain & palliative care pharmacotherapy, 2021, Volume: 35, Issue:2 Topics: Appetite; Depressive Disorder, Major; Humans; Hunger; Male; Mianserin; Middle Aged; Mirtazapine	2021
Mirtazapine use may increase the risk of hypothyroxinaemia in patients affected by major depressive disorder. British journal of clinical pharmacology, 2022, Volume: 88, Issue:1 Topics: Depressive Disorder, Major; Humans; Incidence; Mirtazapine; Retrospective Studies	2022
Drug use evaluation: A two-year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder. Brain and behavior, 2021, Volume: 11, Issue:8 Topics: Acetamides; Depressive Disorder, Major; Humans; Mirtazapine; Pharmaceutical Preparations; Retrospect	2021
Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection. Brain, behavior, and immunity, 2017, Volume: 66 Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricy	2017
Mirtazapine-associated pancreatitis. Medicina clinica, 2018, 03-09, Volume: 150, Issue:5 Topics: Aged, 80 and over; Antidepressive Agents; Causality; Depressive Disorder, Major; Female; Humans; Mir	2018
Translating the HAM-D into the MADRS and vice versa with equipercentile linking. Journal of affective disorders, 2018, 01-15, Volume: 226 Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Depressive Disorder, Major; Female; Humans; Mal	2018
Differentially expressed genes related to major depressive disorder and antidepressant response: genome-wide gene expression analysis. Experimental & molecular medicine, 2018, 08-03, Volume: 50, Issue:8 Topics: Aged; Antidepressive Agents; Case-Control Studies; Cluster Analysis; Depressive Disorder, Major; Fem	2018
Orthorexia nervosa and comorbid depression successfully treated with mirtazapine: a case report. Eating and weight disorders : EWD, 2020, Volume: 25, Issue:1 Topics: Adolescent; Antidepressive Agents; Depressive Disorder, Major; Feeding and Eating Disorders; Female;	2020
Other Antidepressants. Handbook of experimental pharmacology, 2019, Volume: 250 Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Mirtazapine; Selective Serotonin Reuptake	2019
Fourteen-Pound Fluvoxamine-Associated Weight Gain in a Young Woman with Depression and Multiple Anxiety Symptoms. Journal of child and adolescent psychopharmacology, 2018, Volume: 28, Issue:7 Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety	2018
Treatment of phantom shocks: A case report. International journal of psychiatry in medicine, 2019, Volume: 54, Issue:3 Topics: Antidepressive Agents; Anxiety Disorders; Cocaine-Related Disorders; Defibrillators, Implantable; De	2019
Mirtazapine-Induced Epistaxis in an Australian Indigenous Man. The primary care companion for CNS disorders, 2018, Oct-25, Volume: 20, Issue:5 Topics: Adolescent; Australia; Depressive Disorder, Major; Epistaxis; Humans; Male; Mirtazapine; Native Hawa	2018
Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. The American journal of psychiatry, 2019, 05-01, Volume: 176, Issue:5 Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Fe	2019
Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. The American journal of psychiatry, 2019, 05-01, Volume: 176, Issue:5 Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Fe	2019
Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. The American journal of psychiatry, 2019, 05-01, Volume: 176, Issue:5 Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Fe	2019
Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. The American journal of psychiatry, 2019, 05-01, Volume: 176, Issue:5 Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Fe	2019
Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. The American journal of psychiatry, 2019, 05-01, Volume: 176, Issue:5 Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Fe	2019
Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. The American journal of psychiatry, 2019, 05-01, Volume: 176, Issue:5 Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Fe	2019
Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. The American journal of psychiatry, 2019, 05-01, Volume: 176, Issue:5 Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Fe	2019
Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. The American journal of psychiatry, 2019, 05-01, Volume: 176, Issue:5 Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Fe	2019
Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. The American journal of psychiatry, 2019, 05-01, Volume: 176, Issue:5 Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Fe	2019
Which antidepressant doses are optimal? The lancet. Psychiatry, 2019, Volume: 6, Issue:7 Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Mirtazapine; Selective Serotonin Reuptake	2019
Antidepressants Reduced Risk of Mortality in Patients With Diabetes Mellitus: A Population-Based Cohort Study in Taiwan. The Journal of clinical endocrinology and metabolism, 2019, 10-01, Volume: 104, Issue:10 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cohort Studies; Co	2019
Mirtazapine-induced galactorrhea: a case report. The Journal of neuropsychiatry and clinical neurosciences, 2013,Spring, Volume: 25, Issue:2 Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; Galactorrhea; Humans; M	2013
Visual and auditory hallucinations associated with citalopram treatment. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:4 Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depressive D	2013
Real-world, open-label study to evaluate the effectiveness of mirtazapine on sleep quality in outpatients with major depressive disorder. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2014, Volume: 6, Issue:2 Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Middle Ag	2014
[Antidepressant treatment associated hyponatremia -- case report]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2013, Volume: 15, Issue:3 Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Critical Care; Cyc	2013
A pilot study to evaluate symptom-oriented selection of antidepressants in patients with cancer. Journal of palliative medicine, 2014, Volume: 17, Issue:2 Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depressive D	2014
Interaction of 5-HTT and HTR1A gene polymorphisms in treatment responses to mirtazapine in patients with major depressive disorder. Journal of clinical psychopharmacology, 2014, Volume: 34, Issue:4 Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Epistasis, Genetic; Female; Hum	2014
Acute hepatitis after starting pinaverium bromide in a patient taking mirtazapine. BMJ case reports, 2014, Jul-11, Volume: 2014 Topics: Acute Disease; Biopsy; Depressive Disorder, Major; Diagnosis, Differential; Drug Therapy, Combinatio	2014
Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: effect of antidepressant treatment. Neuropharmacology, 2014, Volume: 86 Topics: Amino Acids; Animals; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Down-Regulation	2014
Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation. Journal of psychiatric research, 2014, Volume: 59 Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents, Tricyclic; Brain-Derived Neurotrophic Fact	2014
Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine. Journal of psychopharmacology (Oxford, England), 2015, Volume: 29, Issue:5 Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Arrestins; beta-Arrestin 1; beta-Arrestins; Depressiv	2015
Transcranial magnetic stimulation as an antidepressant alternative in a patient with Brugada syndrome and recurrent syncope. Mayo Clinic proceedings, 2014, Volume: 89, Issue:11 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Brugada Syndrome;	2014
Dynamics of melanin-concentrating hormone (MCH) serum levels in major depressive disorder during antidepressant treatment. Journal of affective disorders, 2015, Jul-15, Volume: 180 Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Dr	2015
Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants. Behavioural brain research, 2015, Oct-01, Volume: 292 Topics: Adult; Antidepressive Agents; Biomarkers, Pharmacological; Case-Control Studies; Citalopram; Cortico	2015
Mirtazapine-induced acute angle closure. Indian journal of ophthalmology, 2015, Volume: 63, Issue:6 Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; Glaucoma, Angle-Closure	2015
[Cognitive dysfunction in major depression]. MMW Fortschritte der Medizin, 2015, Sep-24, Volume: 157, Issue:16 Topics: Attention; Cognition Disorders; Depressive Disorder, Major; Drug Therapy, Combination; Executive Fun	2015
Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression. Pharmacology, 2016, Volume: 97, Issue:3-4 Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Brain-Derived Neurotrophic Factor; Depression;	2016
Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients. Translational psychiatry, 2016, 05-31, Volume: 6, Issue:5 Topics: Adult; Biomarkers; Cell Proliferation; Depressive Disorder, Major; Depressive Disorder, Treatment-Re	2016
Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach. JAMA psychiatry, 2017, Apr-01, Volume: 74, Issue:4 Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents; Bupropion; Citalopram; Cluster Analysis; Dep	2017
Endothelial nitric oxide synthase in rat brain is downregulated by sub-chronic antidepressant treatment. Psychopharmacology, 2017, Volume: 234, Issue:11 Topics: Animals; Antidepressive Agents; Brain; Cyclopropanes; Depressive Disorder, Major; Down-Regulation; D	2017
Antidepressant-associated mania: soon after switch from fluoxetine to mirtazapine in an elderly woman with mixed depressive features. Journal of psychopharmacology (Oxford, England), 2009, Volume: 23, Issue:2 Topics: Adrenergic alpha-Antagonists; Aged; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Rela	2009
Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:5 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexano	2008
[Combining venlafaxine and mirtazapine for the treatment of major depression with dysthymia--"double depression"]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2008, Volume: 30, Issue:3 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; De	2008
Hyperglycaemia secondary to mirtazapine therapy in a 37-year-old man. The Australian and New Zealand journal of psychiatry, 2008, Volume: 42, Issue:11 Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Drug Therapy, Combination; Glic	2008
Mirtazapine-induced manic switch in adolescent unipolar depression. The Australian and New Zealand journal of psychiatry, 2008, Volume: 42, Issue:12 Topics: Adolescent; Antidepressive Agents, Tricyclic; Antimanic Agents; Bipolar Disorder; Depressive Disorde	2008
Optimal use of antidepressants: when to act? Journal of psychiatry & neuroscience : JPN, 2009, Volume: 34, Issue:1 Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Humans; Mianser	2009
MAOA gene polymorphisms and response to mirtazapine in major depression. Human psychopharmacology, 2009, Volume: 24, Issue:4 Topics: Adult; Aged; Apolipoproteins E; Depressive Disorder, Major; DNA; Female; Humans; Male; Mianserin; Mi	2009
Association of the adrenergic alpha 2a receptor--1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder. Brain research, 2009, Mar-25, Volume: 1262 Topics: Adrenergic alpha-Antagonists; Adult; Depressive Disorder, Major; Female; Genetic Predisposition to D	2009
Mirtazapine and hyperpigmentation. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:4 Pt 2 Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dermatitis, Phototoxic; Dose-Re	2009
Antidepressant switching among adherent patients treated for depression. Psychiatric services (Washington, D.C.), 2009, Volume: 60, Issue:5 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Dep	2009
Early adversity in chronic depression: clinical correlates and response to pharmacotherapy. Depression and anxiety, 2009, Volume: 26, Issue:8 Topics: Adolescent; Adult; Age of Onset; Aged; Algorithms; Antidepressive Agents; Anxiety Disorders; Bupropi	2009
[11C]Mirtazapine binding in depressed antidepressant nonresponders studied by PET neuroimaging. Psychopharmacology, 2009, Volume: 206, Issue:1 Topics: Adult; Antidepressive Agents, Tricyclic; Brain; Carbon Radioisotopes; Depressive Disorder, Major; Dr	2009
Cortisol metabolism in depressed patients and healthy controls. Neuroendocrinology, 2009, Volume: 90, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri	2009
Neurotrophic factors in serum following ECT: a pilot study. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Combined Modality Therapy; Cyclohexanols; Depressi	2009
Use of mirtazapine in an adult with refractory anorexia nervosa and comorbid depression: a case report. The International journal of eating disorders, 2011, Volume: 44, Issue:2 Topics: Anorexia Nervosa; Antidepressive Agents, Tricyclic; Body Weight; Depressive Disorder, Major; Female;	2011
Combining antidepressant medications: a good idea? The American journal of psychiatry, 2010, Volume: 167, Issue:3 Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Dr	2010
Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment. Pharmacotherapy, 2010, Volume: 30, Issue:4 Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Depressive Disorder, Major; Dreams; Ha	2010
Sertraline-induced serotonin syndrome followed by mirtazapine reaction. Progress in neuro-psychopharmacology & biological psychiatry, 2010, Aug-16, Volume: 34, Issue:6 Topics: Adult; Antidepressive Agents; Cyproheptadine; Depressive Disorder, Major; Humans; Male; Mianserin; M	2010
Mirtazapine-associated urinary retention. The Journal of neuropsychiatry and clinical neurosciences, 2010,Summer, Volume: 22, Issue:3 Topics: Aged, 80 and over; Depressive Disorder, Major; Humans; Male; Mianserin; Mirtazapine; Urinary Retenti	2010
Vitamin B6 treatment of oedema induced by mirtazapine and isocarboxazid. Acta psychiatrica Scandinavica, 2011, Volume: 124, Issue:1 Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Edema; Humans;	2011
Mirtazapine-induced hepatocellular-type liver injury. The Annals of pharmacotherapy, 2011, Volume: 45, Issue:6 Topics: Antidepressive Agents, Tricyclic; Chemical and Drug Induced Liver Injury; Depressive Disorder, Major	2011
Mirtazapine induced mania in a woman with major depression in the absence of features of bipolarity. The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:10 Topics: Adult; Antidepressive Agents, Tricyclic; Bipolar Disorder; Depressive Disorder, Major; Female; Human	2011
Complexity analysis of spontaneous brain activity: effects of depression and antidepressant treatment. Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:5 Topics: Age Factors; Antidepressive Agents; Brain; Depressive Disorder, Major; Female; Humans; Male; Mianser	2012
Hyponatremia associated with selective serotonin reuptake inhibitors, mirtazapine, and venlafaxine in Korean patients with major depressive disorder. International journal of clinical pharmacology and therapeutics, 2011, Volume: 49, Issue:7 Topics: Adolescent; Adult; Aged; Analysis of Variance; Cyclohexanols; Data Interpretation, Statistical; Depr	2011
Fatal agranulocytosis associated with psychotropic medication use. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012, May-15, Volume: 69, Issue:10 Topics: Adult; Agranulocytosis; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Ag	2012
[Optimizing antidepressant pharmacotherapy in a case of inflammatory bowel disease and major depression]. Psychiatrische Praxis, 2012, Volume: 39, Issue:5 Topics: Alleles; Anti-Inflammatory Agents; Antidepressive Agents, Tricyclic; Colitis, Ulcerative; Combined M	2012
What is a rational antidepressant treatment for major depression in patients with Parkinson's disease? Psychiatry and clinical neurosciences, 2012, Volume: 66, Issue:5 Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; Humans; Mianserin; Middle Aged	2012
Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). CNS spectrums, 2012, Volume: 17, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Asian People; Brain-Derived Neurotrophic Fact	2012
Saliva levels of 3-methoxy-4-hydroxyphenylglycol and clinical efficacy of mirtazapine or selective serotonin reuptake inhibitors in patients with major depression. Human psychopharmacology, 2013, Volume: 28, Issue:1 Topics: Adult; Aged; Biomarkers; Depressive Disorder, Major; Female; Humans; Male; Methoxyhydroxyphenylglyco	2013
Antidepressant use in underweight older adults. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2012, Volume: 27, Issue:12 Topics: Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents; Appetite; Body Mass Index; Body Weigh	2012
Functional dyspepsia and mirtazapine. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2002, Volume: 47, Issue:6 Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dyspepsia; Female; Humans; Limbic Syst	2002
Restless legs syndrome induced by mirtazapine. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:12 Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Male; Mianserin; Middle Aged; Mirtazapine	2002
Serotonin transporter modulation in blood lymphocytes from patients with major depression. Cellular and molecular neurobiology, 2002, Volume: 22, Issue:5-6 Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents, Second-Generation; Brain; Carrier Protei	2002
Attenuation of HPA axis hyperactivity and simultaneous clinical deterioration in a depressed patient treated with mirtazapine. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2001, Volume: 2, Issue:2 Topics: Adrenocorticotropic Hormone; Antidepressive Agents, Tricyclic; Corticotropin-Releasing Hormone; Depr	2001
Mirtazapine for treatment-resistant depression: a preliminary report. Journal of psychiatry & neuroscience : JPN, 2003, Volume: 28, Issue:1 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Ma	2003
The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England. Journal of psychopharmacology (Oxford, England), 2003, Volume: 17, Issue:1 Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tri	2003
Modafinil augmentation of mirtazapine in a failure-to-thrive geriatric inpatient. International journal of psychiatry in medicine, 2002, Volume: 32, Issue:4 Topics: Aged; Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cachexia; Central Nervous System Stimu	2002
Influence of mirtazapine on urinary free cortisol excretion in depressed patients. Psychiatry research, 2003, Oct-15, Volume: 120, Issue:3 Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Response Relationship, Dru	2003
Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2004, Volume: 29, Issue:3 Topics: Adult; Analysis of Variance; beta-Adrenergic Receptor Kinases; Blood Platelets; Chi-Square Distribut	2004
The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. The pharmacogenomics journal, 2005, Volume: 5, Issue:1 Topics: Adult; Catechol O-Methyltransferase; Depressive Disorder, Major; Female; Humans; Male; Methionine; M	2005
[Motivational therapy can fail here. Sleep disorders in depressions]. MMW Fortschritte der Medizin, 2004, Aug-19, Volume: 146, Issue:33-34 Topics: Antidepressive Agents, Tricyclic; Arousal; Citalopram; Depressive Disorder, Major; Dose-Response Rel	2004
Mirtazapine for treatment of nausea induced by selective serotonin reuptake inhibitors. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2004, Volume: 49, Issue:10 Topics: Depressive Disorder, Major; Female; Histamine H1 Antagonists; Humans; Mianserin; Middle Aged; Mirtaz	2004
Re-administration of mirtazapine could overcome previous mirtazapine- associated restless legs syndrome? Psychiatry and clinical neurosciences, 2004, Volume: 58, Issue:6 Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; Humans; Mianserin; Middle Aged	2004
Acute reversible dyskinesia induced by mirtazapine. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:6 Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Humans; Male	2005
Mirtazapine increases cortical excitability in healthy controls and epilepsy patients with major depression. Journal of neurology, neurosurgery, and psychiatry, 2005, Volume: 76, Issue:4 Topics: Adult; Antidepressive Agents, Tricyclic; Arousal; Depressive Disorder, Major; Electric Stimulation;	2005
Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients. International immunopharmacology, 2005, Volume: 5, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cell Membrane; De	2005
Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2005, Volume: 50, Issue:3 Topics: Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dos	2005
Sertraline- and mirtazapine-induced severe neutropenia. The American journal of psychiatry, 2005, Volume: 162, Issue:7 Topics: Adult; Agranulocytosis; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; Humans	2005
Changes in regional cerebral blood flow by therapeutic vagus nerve stimulation in depression: an exploratory approach. Psychiatry research, 2005, Aug-30, Volume: 139, Issue:3 Topics: Adult; Amygdala; Antidepressive Agents, Tricyclic; Brain; Cerebrovascular Circulation; Citalopram; C	2005
Does domperidone potentiate mirtazapine-associated restless legs syndrome? Progress in neuro-psychopharmacology & biological psychiatry, 2006, Volume: 30, Issue:2 Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Domperidone; Dopamine Antagonis	2006
Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression. Progress in neuro-psychopharmacology & biological psychiatry, 2006, Volume: 30, Issue:2 Topics: Adult; Anorexia Nervosa; Antidepressive Agents, Tricyclic; Antiemetics; Benzodiazepines; Depressive	2006
Massive creatine kinase elevations with quetiapine: report of two cases. Pharmacopsychiatry, 2006, Volume: 39, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Creatine Kinase; Depressive Disorder,	2006
Re: Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2005, Volume: 50, Issue:13 Topics: Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Depressive Disorder, Major; Drug Resist	2005
A case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:5 Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Comorbidity; Depressive Disorder, Maj	2006
Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study. Psychopharmacology bulletin, 2007, Volume: 40, Issue:1 Topics: Activities of Daily Living; Administration, Oral; Aged; Antidepressive Agents, Tricyclic; Comorbidit	2007
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials. Psychiatry research, 2007, Aug-30, Volume: 152, Issue:2-3 Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disord	2007
Cannabinoid hyperemesis: marijuana puts patients in hot water. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2007, Volume: 15, Issue:2 Topics: Abdominal Pain; Adult; Antidepressive Agents, Tricyclic; Cannabinoids; Cognitive Behavioral Therapy;	2007
Successful mirtazapine treatment of an 81-year-old patient with syndrome of inappropriate antidiuretic hormone secretion. Pharmacopsychiatry, 2007, Volume: 40, Issue:3 Topics: Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cital	2007
Mirtazapine for anorexia nervosa with depression. The Australian and New Zealand journal of psychiatry, 2007, Volume: 41, Issue:9 Topics: Adolescent; Anorexia Nervosa; Antidepressive Agents, Tricyclic; Body Weight; Cognitive Behavioral Th	2007
Comments on "Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder". Progress in neuro-psychopharmacology & biological psychiatry, 2008, Feb-15, Volume: 32, Issue:2 Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Gene Expression; Genetic Variation; Hu	2008
Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression. Neuropsychobiology, 2007, Volume: 56, Issue:1 Topics: Antidepressive Agents, Tricyclic; Asian People; Depressive Disorder, Major; Female; Genotype; Hetero	2007
Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:1 Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Comb	2008
Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. International journal of psychiatry in medicine, 2007, Volume: 37, Issue:3 Topics: Antidepressive Agents, Tricyclic; Asian People; Case-Control Studies; Depressive Disorder, Major; Fe	2007
Restless legs syndrome as side effect of second generation antidepressants. Journal of psychiatric research, 2008, Volume: 43, Issue:1 Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Depressive Disorder, M	2008
Sexual functioning in depressed outpatients taking mirtazapine. Depression and anxiety, 1999, Volume: 9, Issue:4 Topics: Adult; Ambulatory Care; Depressive Disorder, Major; Ejaculation; Female; Humans; Male; Mianserin; Mi	1999
Treatment-refractory depression successfully treated with the combination of mirtazapine and lithium. Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:2 Topics: Antidepressive Agents, Tricyclic; Antimanic Agents; Depressive Disorder, Major; Drug Therapy, Combin	2000
Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biological psychiatry, 2000, Jul-01, Volume: 48, Issue:1 Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive	2000
Occurrence of mirtazapine-induced delirium in organic brain disorder. International clinical psychopharmacology, 2000, Volume: 15, Issue:4 Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Delirium; Depressive Disorder, Major; Fem	2000
Treatment of mood-congruent psychotic depression with imipramine. Journal of affective disorders, 2001, Volume: 66, Issue:2-3 Topics: Adolescent; Adult; Affect; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Im	2001
Intravenous mirtazapine in the treatment of depressed inpatients. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2002, Volume: 12, Issue:1 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Analysis of Variance; Behavior; Depressive Disorder, Majo	2002
Mirtazapine, but not fluvoxamine, normalizes the blunted REM sleep response to clonidine in depressed patients: implications for subsensitivity of alpha(2)-adrenergic receptors in depression. Psychiatry research, 2002, Jan-31, Volume: 109, Issue:1 Topics: Adrenergic alpha-Agonists; Antidepressive Agents, Tricyclic; Clonidine; Depressive Disorder, Major;	2002
Serotonin syndrome and atypical antipsychotics. The American journal of psychiatry, 2002, Volume: 159, Issue:4 Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major;	2002

mirtazapine and Depression, Involutional

Research Excerpts

Research

Studies (238)

Authors

Clinical Trials (19)

Trial Overview

Trial Outcomes

Quality of Life Inventory

Quick Inventory of Depressive Symptoms

Drinks Per Drinking Day

Level of Depressive Symptoms

Drinks Per Drinking Day

Level of Depressive Symptoms

Reviews

Trials

Other Studies